This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kouides, P. A. Articles by Bennett, J. M. Search for Related Content PubMed PubMed Citation Articles by Kouides, P. A. Articles by Bennett, J. M.

Understanding the Myelodysplastic Syndromes

University of Rochester School of Medicine and Dentistry, Department of Medicine, Rochester General Hospital, Rochester, New York, USA

Correspondence: Peter A. Kouides, M.D., Rochester General Hospital, Hematology Unit, Box 266, 1425 Portland Avenue, Rochester, New York 14621, USA. Telephone 716-338-4081; Fax: 716-338-2347; e-mail: pkouides{at}rghnet.edu

The myelodysplastic syndrome (MDS) remains challenging to the clinician in terms of diagnosis and management. The diagnosis is essentially one of exclusion in first ruling out other disorders that can also cause peripheral blood/bone marrow cell dysplasia and cytopenias. The distinguishing biological characteristic of MDS is that it is a clonal disorder of the marrow with impaired differentiation. Recent studies implicate extensive apoptosis as the explanation of the paradoxical observation of marrow hyperplasia but peripheral blood cytopenia. Neutropenia and/or neutrophil dysfunction account for the primary clinical manifestation of MDS in terms of an increased risk for infection, which is the leading cause of death in MDS. The clonal nature of MDS places it also at continual risk for transformation to acute leukemia. Predicting overall survival as well as the risk of AML transformation has been improved by the recent development of a scoring system (International Prognostic Scoring System) that incorporates three laboratory variables: percent of marrow blasts, degree of cytopenias, and presence of chromosomal abnormalities. Based on these variables, four prognostic subgroups can be delineated ranging from low risk with a median survival of 5.7 years, to high risk with a median survival of 0.4 years. Management of MDS can now be based on the patient’s respective prognostic subgrouping, with low-risk patients being considered for hematopoietic growth factor singly or in combination if at the point of red cell transfusion dependence and/or neutropenia with recurrent infections, while high-risk patients should be offered AML-induction therapy or novel agents such as Topotecan. One must individualize further in patients in the remaining intermediate groups, I and II, in choosing the most appropriate therapy. Future advances upon understanding the molecular details of the MDS clone should ultimately improve the care of patients with MDS.

Key Words. Myelodysplastic syndrome • Apoptosis • International Prognostic Scoring System • Topotecan • Bone marrow transplantation • Erythropoietin

This article has been cited by other articles:

				S. D. Ross, I. E. Allen, C. A. Probst, B. Sercus, S. M. Crean, and G. Ranganathan Efficacy and Safety of Erythropoiesis-Stimulating Proteins in Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis Oncologist, October 1, 2007; 12(10): 1264 - 1273. [Abstract] [Full Text] [PDF]

				G. M. Fuhler, N. R. Blom, P. J. Coffer, A. L. Drayer, and E. Vellenga The reduced GM-CSF priming of ROS production in granulocytes from patients with myelodysplasia is associated with an impaired lipid raft formation J. Leukoc. Biol., February 1, 2007; 81(2): 449 - 457. [Abstract] [Full Text] [PDF]

				Y. Shikama, T. Shichishima, I. Matsuoka, P. T. Jubinsky, C. A. Sieff, and Y. Maruyama Accumulation of an intron-retained mRNA for granulocyte macrophage-colony stimulating factor receptor common {beta} chain in neutrophils of myelodysplastic syndromes J. Leukoc. Biol., May 1, 2005; 77(5): 811 - 819. [Abstract] [Full Text] [PDF]

				G. M. Fuhler, G. J. Knol, A. L. Drayer, and E. Vellenga Impaired interleukin-8- and GRO{alpha}-induced phosphorylation of extracellular signal-regulated kinase result in decreased migration of neutrophils from patients with myelodysplasia J. Leukoc. Biol., February 1, 2005; 77(2): 257 - 266. [Abstract] [Full Text] [PDF]

				G. M. Fuhler, K. A. Cadwallader, G. J. Knol, E. R. Chilvers, A. L. Drayer, and E. Vellenga Disturbed granulocyte macrophage-colony stimulating factor priming of phosphatidylinositol 3,4,5-trisphosphate accumulation and Rac activation in fMLP-stimulated neutrophils from patients with myelodysplasia J. Leukoc. Biol., July 1, 2004; 76(1): 254 - 262. [Abstract] [Full Text] [PDF]

				S. Giannouli, M. Voulgarelis, E. Zintzaras, A. G. Tzioufas, and H. M. Moutsopoulos Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study Rheumatology, May 1, 2004; 43(5): 626 - 632. [Abstract] [Full Text] [PDF]

				G. M. Fuhler, A. L. Drayer, and E. Vellenga Decreased phosphorylation of protein kinase B and extracellular signal-regulated kinase in neutrophils from patients with myelodysplasia Blood, February 1, 2003; 101(3): 1172 - 1180. [Abstract] [Full Text] [PDF]

				M. Albitar, T. Manshouri, Y. Shen, D. Liu, M. Beran, H. M. Kantarjian, A. Rogers, I. Jilani, C. W. Lin, S. Pierce, et al. Myelodysplastic syndrome is not merely "preleukemia" Blood, July 18, 2002; 100(3): 791 - 798. [Abstract] [Full Text] [PDF]